Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and CIBINQO.
Developed by Pfizer, abrocitinib has received marketing authorization for abrocitinib in adults with moderate-to-severe atopic dermatitis from the Central Drugs Standard Control Organization (CDSCO). It is also approved by the USFDA, European Medicines Agency (EMA), and other regulatory agencies.
Abrocitinib first-of-its-kind oral therapy therapy for adults with moderate-to-severe AD, a chronic skin disease that causes inflammation of the skin and skin barrier defects.
Abrocitinib, a Janus kinase 1 (JAK1) inhibitor, provides rapid itch relief, sustained control of the disease and improved quality of life.
Abrocitinib sold under brand name CIBINQO is launched in over 35 markets globally, including the US, Japan, and China.”Our collaboration with Glenmark will help leverage the collective strengths and capabilities of our organizations to make this breakthrough therapy available to patients and physicians across our country,” said Meenakshi Nevatia, country president and managing director of Pfizer India.“The prevalence of atopic dermatitis in India has been reported to be increasing owing to changes in environmental factors with symptoms appearing during the initial years of life in around 80% of patients,” said Alok Malik, president and business head, India Formulations, Glenmark.
“Being a leader in dermatology therapy in India, this partnership will help us ensure availability of this effective treatment for the Indian patients suffering from moderate-to-severe AD; and further strengthen our position in the dermatology therapy
space,” Malik added.
Approximately 5.9% of adults in India are affected by AD, of which 4.4% suffer from a severe form of this disease. The symptoms of AD, like itching and lack of sleep, lay a significant burden on the patients and their caretakers, affecting multiple aspects including their quality of life and mental health.
(You can now subscribe to our Economic Times WhatsApp channel)
